dimethyl 4-[2-[4-(2-hydroxy-3-phenoxypropylamino)butoxy]-5-methylsulfinylphenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate | 103434-54-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: dimethyl 4-[2-[4-(2-hydroxy-3-phenoxypropylamino)butoxy]-5-methylsulfinylphenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• 英文别名: Dimethyl 4-[2-[4-[(2-hydroxy-3-phenoxypropyl)amino]butoxy]-5-methylsulfinylphenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 103434-54-4
• 化学式: C₃₁H₄₀N₂O₈S
• 分子量: 600.733
• InChiKey: YDZMMXPWYRSZDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  42
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  152
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• Dihydropyridine compounds, their production, and pharmaceutical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0167371A2

  公开（公告）日：1986-01-08

  The invention provides a dihydropyridine compound of the following general formular (I) or a salt thereof: wherein R' and R2 are the same or different and selected from C, to C10 alkyl groups, C, to C5 alkyl groups interrupted by oxygen atom(s), and C, to C5 alkyl groups substituted by C3 to C6 alicyclic group(s); R3 and R4 are the same or different C, to C5 alkyl groups; R5 and R6 are the same or different and selected from hydrogen and halogen atoms and nitro, C, to C5 alkyl, C, to C5 alkoxy, C, to C5 alkylthio, C, to C5 alkylsulfonyl and C, to C5 alkylsulfinyl groups; R7 and R8 are the same or different and are selected from hydrogen and halogen atoms and cyano, C, to C5 alkoxy and C, to C5 alkanoylamino groups or combine to form, with the adjacent phenyl group, a naphthyl group; A represents a single bond, or a vinylene (-CH=CH-) or ethynylene group (-C≡C-); B represents a single bond or -CH20-; and m and n are the same or different and selected from 0 and integers of 1 to 5, and methods of making such a compound. The compounds may be used for treatment or prevention of ischemic heart-disease and cardiovascular disorders and may show both Ca2+-antagonistic action and adrenergic betareceptor

  本发明提供了以下通式（I）的二氢吡啶化合物或其盐： 其中R'和R2相同或不同，选自C～C10烷基、被氧原子间断的C～C5烷基和被C3～C6脂环基取代的C～C5烷基；R3 和 R4 是相同或不同的 C 至 C5 烷基；R5 和 R6 是相同或不同的选自氢和卤素原子及硝基、C 至 C5 烷基、C 至 C5 烷氧基、C 至 C5 烷硫基、C 至 C5 烷磺酰基和 C 至 C5 烷基亚磺酰基的基团；R7 和 R8 相同或不同，选自氢和卤素原子、氰基、C, 至 C5 烷氧基和 C, 至 C5 烷酰胺基，或与相邻苯基结合形成萘基；A代表单键，或乙烯基（-CH=CH-）或乙炔基（-C≡C-）；B代表单键或-CH20-；m和n相同或不同，选自0和1至5的整数，以及制造这种化合物的方法。这些化合物可用于治疗或预防缺血性心脏病和心血管疾病，并可同时显示出 Ca2+ 拮抗作用和肾上腺素能 betareceptor
• US4727082A
  申请人：——

  公开号：US4727082A

  公开（公告）日：1988-02-23